Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination therapy** consisting of three drugs: **amoxicillin**, **clavulanate** (as clavulanic acid), and **clarithromycin**. - **Amoxicillin** is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. - **Clavulanate** acts as a beta-lactamase inhibitor, protecting amoxicillin from enzymatic degradation and thereby broadening its spectrum against beta-lactamase producing organisms. - **Clarithromycin** is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. This combination does not correspond to a common branded product, but the pairing of amoxicillin and clarithromycin (often with other agents such as a proton pump inhibitor) is used for the eradication of **Helicobacter pylori** infection. Clavulanate is sometimes added to amoxicillin to extend its activity spectrum. The triple combination has also shown synergistic in vitro bactericidal activity against organisms like *Mycobacterium ulcerans*, and has been explored for severe or resistant infections where broad-spectrum and dual-mechanism coverage is necessary[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amoxicillin + clavulanate + clarithromycin.